In the wake of a failed late-stage study evaluating rivipansel for the treatment of vaso-occlusive crisis in sickle cell disease patients, Pfizer (PFE +0.4%) has notified licensor GlycoMimetics (GLYC +1.7%) that it will terminate their 2011 agreement.
GLYC will regain all rights to respective assets and will incur no termination penalties related to the end of the partnership.
https://seekingalpha.com/news/3540669-pfizer-axes-license-agreement-glycomimetics
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.